3//SEC Filing
NeoMed Innovation V Ltd 3
Accession 0000899243-18-027720
CIK 0001603756other
Filed
Oct 29, 8:00 PM ET
Accepted
Oct 30, 9:14 PM ET
Size
13.2 KB
Accession
0000899243-18-027720
Insider Transaction Report
Form 3
NeoMed Innovation V Ltd
10% Owner
Holdings
- (indirect: By NeoMed Innovation V, L.P.)
Series A Preferred Stock
→ Common Stock (451,738 underlying) - (indirect: By NeoMed Innovation V, L.P.)
Series B-1 Preferred Stock
→ Common Stock (455,610 underlying) - (indirect: By NeoMed Innovation V, L.P.)
Series B-2 Preferred Stock
→ Common Stock (243,750 underlying) - (indirect: By NeoMed Innovation V, L.P.)
Series C Preferred Stock
→ Common Stock (369,786 underlying)
NeoMed Innovation V L.P.
10% Owner
Holdings
- (indirect: By NeoMed Innovation V, L.P.)
Series B-2 Preferred Stock
→ Common Stock (243,750 underlying) - (indirect: By NeoMed Innovation V, L.P.)
Series B-1 Preferred Stock
→ Common Stock (455,610 underlying) - (indirect: By NeoMed Innovation V, L.P.)
Series C Preferred Stock
→ Common Stock (369,786 underlying) - (indirect: By NeoMed Innovation V, L.P.)
Series A Preferred Stock
→ Common Stock (451,738 underlying)
Footnotes (6)
- [F1]Each share of Series A preferred stock is convertible, at any time, at the reporting person's election, into shares of the Issuer's common stock at the then-effective conversion rate for no additional consideration in accordance with the Issuer's Fourth Amended and Restated Certificate of Incorporation, as amended to date. In addition, effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of the Series A preferred stock will automatically convert into 2.31660 shares of the Issuer's common stock. The Series A preferred stock has no expiration date.
- [F2]Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018.
- [F3]The shares are held of record by NeoMed Innovation V, L.P. ("NeoMed"). NeoMed Innovation V Limited is the general partner of NeoMed and has voting and dispositive power over the shares held by NeoMed. Erik Amble, Ph.D., who is a member of the Issuer's board of directors, is a director of NeoMed Innovation V Limited, and may be deemed to have voting and dispositive power over the shares held by NeoMed. Mr. Amble disclaims beneficial ownership of these securities and this report shall not be deemed an admission that Mr. Amble is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his respective pecuniary interest therein.
- [F4]Each share of Series B-1 preferred stock is convertible, at any time, at the reporting person's election, into shares of the Issuer's common stock at the then-effective conversion rate for no additional consideration in accordance with the Issuer's Fourth Amended and Restated Certificate of Incorporation, as amended to date. In addition, effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of the Series B-1 preferred stock will automatically convert into 1.2 shares of the Issuer's common stock. The Series B-1 preferred stock has no expiration date.
- [F5]Each share of Series B-2 preferred stock is convertible, at any time, at the reporting person's election, into shares of the Issuer's common stock at the then-effective conversion rate for no additional consideration in accordance with the Issuer's Fourth Amended and Restated Certificate of Incorporation, as amended to date. In addition, effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of the Series B-2 preferred stock will automatically convert into 1.2 shares of the Issuer's common stock. The Series B-2 preferred stock has no expiration date.
- [F6]Each share of Series C preferred stock is convertible, at any time, at the reporting person's election, into shares of the Issuer's common stock at the then-effective conversion rate for no additional consideration in accordance with the Issuer's Fourth Amended and Restated Certificate of Incorporation, as amended to date. In addition, effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of the Series C preferred stock will automatically convert into 1.2 shares of the Issuer's common stock. The Series C preferred stock has no expiration date.
Documents
Issuer
Axonics Modulation Technologies, Inc.
CIK 0001603756
Entity typeother
IncorporatedJersey
Related Parties
1- filerCIK 0001722666
Filing Metadata
- Form type
- 3
- Filed
- Oct 29, 8:00 PM ET
- Accepted
- Oct 30, 9:14 PM ET
- Size
- 13.2 KB